Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Phase 2 hypofractionation study usion proton beam therapy for prostate adenocarcinoma
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1 | Experimental | 27pt/60CGE/20fx/5wks to PGTV(mon, tue, thu, fri; 4/wk) |
|
| Arm 2 | Experimental | 27pt/54CGE/15fx/5wks to PGTV (mon, wed, fri; 3/wk) |
|
| Arm 3 | Experimental | 27pt / 47CGE/10fx/5wk to PGTV(tue, thu;2/wk) |
|
| Arm 4 | Experimental | 27pt/ 35CGE/ 5fx/2.5wk to PGTV(the, thu; 2/wk) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| proton beam therapy | Radiation | hypofractionation study using proton beam therapy for prostate adenocarcinoma |
|
| Measure | Description | Time Frame |
|---|---|---|
| clinical outcomes | To evaluate biochemical failure-free survival (BCFFS) | up to 5years from a initial follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| acute toxicity | to evaluate acute toxicities by CTCAE version 3.0 | up to 5years from a initial follow-up |
| late toxicity | to evaluated late toxicities by CTCAE version 3.0 |
Not provided
Inclusion Criteria:
Biopsy proven prostate adenocarcinoma Stage: T1-T2cN0M0 ECOG performance status: 0-2 Signed study specific informed consent prior to study entry
Exclusion Criteria:
Postoperative residual or recurrent tumor Evidence of distant metastases Previous irradiation for the tumor in the same location Adjuvant anti-androgenic hormonal therapy High risk group (NCCN guide line)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| kwan ho cho, M.D. | National Cancer Center, Korea | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National cancer center, korea | Goyang-si | Gyeonggi-do | 411-769 | South Korea |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30630500 | Derived | Ha B, Cho KH, Lee KH, Joung JY, Kim YJ, Lee SU, Kim H, Suh YG, Moon SH, Lim YK, Jeong JH, Kim H, Park WS, Kim SH. Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionation. Radiat Oncol. 2019 Jan 10;14(1):4. doi: 10.1186/s13014-019-1210-7. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D061766 | Proton Therapy |
| ID | Term |
|---|---|
| D063193 | Heavy Ion Radiotherapy |
| D011878 | Radiotherapy |
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| up to 5years from a initial follow-up |
| overall survival | to evaluated overall survival | up to 5years from a initial follow-up |